{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:56:36Z","timestamp":1791294996318,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.2515\/therapie:2006067","type":"journal-article","created":{"date-parts":[[2007,3,19]],"date-time":"2007-03-19T09:23:52Z","timestamp":1174296232000},"page":"389-394","source":"Crossref","is-referenced-by-count":4,"title":["Ath\u00e9rothrombose : transposition des mod\u00e8les \u00e0 la clinique et r\u00e9ciproquement"],"prefix":"10.1016","volume":"61","author":[{"given":"Christian","family":"Gachet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Hechler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Nonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Cazenave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Aleil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2006067_bb0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2005-869523","article-title":"Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis","volume":"31","author":"Savi","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.2515\/therapie:2006067_bb0015","first-page":"167","article-title":"L\u2019agr\u00e9gation plaquettaire: outil d\u2019investigation clinique et d\u2019\u00e9tude pharmacologique. M\u00e9thodologie","volume":"41","author":"Cazenave","year":"1983","journal-title":"Ann Biol Clin"},{"key":"10.2515\/therapie:2006067_bb0020","first-page":"13","article-title":"Preparation of washed platelet suspensions from human and rodent blood","volume":"272","author":"Cazenave","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.2515\/therapie:2006067_bb0025","series-title":"Boehringer Ingelheim","article-title":"Introduction \u00e0 l\u2019\u00e9tude de l\u2019h\u00e9mostase et de la thrombose","author":"Boneu","year":"1997"},{"key":"10.2515\/therapie:2006067_bb0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0038-1642759","article-title":"ADP plays a key role in thrombogenesis in rats","volume":"59","author":"Maffrand","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.2515\/therapie:2006067_bb0035","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1172\/JCI111705","article-title":"Functionally thrombasthenic state in normal platelets following the administration of ticlopidine","volume":"75","author":"Di Minno","year":"1985","journal-title":"J Clin Invest"},{"key":"10.2515\/therapie:2006067_bb0040","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2141.1995.tb05319.x","article-title":"Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors","volume":"91","author":"Gachet","year":"1995","journal-title":"Br J Haematol"},{"key":"10.2515\/therapie:2006067_bb0045","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1016\/0006-2952(90)90587-B","article-title":"The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1","volume":"40","author":"Gachet","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"10.2515\/therapie:2006067_bb0050","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1161\/01.ATV.19.10.2281","article-title":"ADP receptors and clinical bleeding disorders","volume":"19","author":"Cattaneo","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2006067_bb0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1432-1033.1992.tb17046.x","article-title":"ADP receptor-induced activation of guanine-nucleotide-binding proteins in human platelet membranes","volume":"207","author":"Gachet","year":"1992","journal-title":"Eur J Biochem"},{"key":"10.2515\/therapie:2006067_bb0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0038-1656322","article-title":"ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes-an effect selectively blocked by the thienopyridine clopidogrel","volume":"68","author":"Gachet","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.2515\/therapie:2006067_bb0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0014-5793(97)00022-7","article-title":"The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells","volume":"403","author":"Leon","year":"1997","journal-title":"FEBS Lett"},{"key":"10.2515\/therapie:2006067_bb0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V92.1.152.413k27_152_159","article-title":"The P2Y1 receptor is necessary for adenosine 5\u2019-diphosphate-induced platelet aggregation","volume":"92","author":"Hechler","year":"1998","journal-title":"Blood"},{"key":"10.2515\/therapie:2006067_bb0075","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0037-1614570","article-title":"The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation","volume":"81","author":"Leon","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.2515\/therapie:2006067_bb0080","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.2515\/therapie:2006067_bb0085","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.2515\/therapie:2006067_bb0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1006\/bbrc.2001.4816","article-title":"P2y(12), a new platelet ADP receptor, target of clopidogrel","volume":"283","author":"Savi","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.2515\/therapie:2006067_bb0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/cyto.10114","article-title":"Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody","volume":"48","author":"Bergmeier","year":"2002","journal-title":"Cytometry"},{"key":"10.2515\/therapie:2006067_bb0100","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1055\/s-0037-1616057","article-title":"A novel monoclonal antibody against the extracellular domain of GPIbbeta modulates vWF mediated platelet adhesion","volume":"86","author":"Perrault","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.2515\/therapie:2006067_bb0105","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00001721-199507000-00012","article-title":"Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species","volume":"6","author":"Ravanat","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.2515\/therapie:2006067_bb0110","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm782","article-title":"Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse","volume":"8","author":"Falati","year":"2002","journal-title":"Nat Med"},{"key":"10.2515\/therapie:2006067_bb0115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.20030144","article-title":"A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo","volume":"198","author":"Hechler","year":"2003","journal-title":"J Exp Med"},{"key":"10.2515\/therapie:2006067_bb0120","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.ATV.0000163184.02484.69","article-title":"Importance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function of lesion severity","volume":"25","author":"Nonne","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2006067_bb0125","first-page":"27E","article-title":"Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC\/AHA guidelines","volume":"14","author":"Mehta","year":"2002","journal-title":"J Invasive Cardiol"},{"key":"10.2515\/therapie:2006067_bb0130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJM199201303260502","article-title":"Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes","volume":"326","author":"Mizuno","year":"1992","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie:2006067_bb0135","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/01.CIR.89.4.1545","article-title":"Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction","volume":"89","author":"TIMI IIIb Trial","year":"1994","journal-title":"Circulation"},{"key":"10.2515\/therapie:2006067_bb0140","first-page":"424","article-title":"La glycoprot\u00e9ine V: un substrat plaquettaire de la thrombine marqueur des thromboses et de la diff\u00e9renciation m\u00e9gacaryocytaire","volume":"6","author":"Lanza","year":"2000","journal-title":"H\u00e9matologie"},{"key":"10.2515\/therapie:2006067_bb0145","first-page":"267","article-title":"La glycoprot\u00e9ine V soluble: un nouveau marqueur plasmatique de la thrombose art\u00e9rielle","volume":"2","author":"Aleil","year":"2004","journal-title":"MT cardiologie"},{"key":"10.2515\/therapie:2006067_bb0150","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1046\/j.1538-7836.2003.00319.x","article-title":"Increased plasma levels of soluble platelet glycoprotein V in patients with acute myocardial infarction","volume":"1","author":"Aleil","year":"2003","journal-title":"J Thromb Haemost"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716304164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716304164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:39:19Z","timestamp":1587429559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716304164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0040595716304164"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2006067","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}